0

Loxiglumide

INQUIRY Add to cart
For Research Use Only | Not For Clinical Use
CATAP107097803
CAS107097-80-3
Structure
MDL NumberMFCD00866772
Molecular Weight461.38
InChI KeyQNQZBKQEIFTHFZ-UHFFFAOYSA-N
Description≥97% (HPLC)
SolubilityDMSO: ≥5 mg/mL
Assay≥97% (HPLC)
Colorwhite to beige
Formpowder
Size10MG, 50MG
Storage Conditions2-8°C
1

Comparison of the Effects of Two Cholecystokinin-Receptor Antagonists, Loxiglumide and L-364,718, on the Pancreatic Secretory Response to Intraduodenal Tryptophan in Dogs

E Niebergall-Roth, S Teyssen, D Wetzel, M Hartel, C Beglinger, R L Riepl, M V Singer

Scand J Gastroenterol. 1996 Jul;31(7):723-32.

PMID: 8819225

1

General Pharmacological Profile of the Novel cholecystokinin-A Antagonist Loxiglumide

T Saito, K Ukai, T Masuda, T Nakagawa, K Kimura, M Fujii, K Wakatsuki, M Saeki, H Kasai

Arzneimittelforschung. 1997 Dec;47(12):1375-82.

PMID: 9450167

1

Inhibitory Effects of a Cholecystokinin Antagonist, Loxiglumide (CR-1505), on the Growth of Freshly Separated and Xenografted Human Pancreatic Cancer

H Morimoto, Y Nio, M Tsubono, C C Tseng, K Kawabata, Y Masai, H Hayashi, N Baba, T Manabe, Y Hosokawa

J Surg Oncol. 1993 May;53(1):47-53.

PMID: 8386784

1

Loxiglumide Rotta Research

Martin Katschinski

IDrugs. 2002 May;5(5):469-74.

PMID: 15570466

1

Role of CCK in Regulation of Pancreaticobiliary Functions and GI Motility in Humans: Effects of Loxiglumide

W E Schmidt, W Creutzfeldt, A Schleser, A R Choudhury, R Nustede, M Höcker, R Nitsche, H Sostmann, L C Rovati, U R Fölsch

Am J Physiol. 1991 Feb;260(2 Pt 1):G197-206.

PMID: 1996640

  • Verification code
Contact Us

Send Us a Request

What is your specific need? We will do everything we can to meet your expectations.
Online Inquiry

Online Inquiry

For any inquiry, question or recommendation, please call: or fill out the following form.

  • Verification code

Head Office

  • Tel:
  • Email:

Follow us on

qrcode